AMGN - アムジェン （Amgen Inc.）

The Dow Jones Industrial Average bulled 750.52 points, or 2.5% higher, in midday trading Tuesday with all 30 components trading higher. Together with Monday''s 765.38-point gain, the two-day rally of 1,516.59 points puts the blue-chip barometer on track for the best two-day performance since it climbed a total of 1,601.33 points on April 6 and April 7 of 2020. On Tuesday, the best performers were shares of Salesforce Inc. , up 5.8% and Boeing Co. , which climbed 5.1%. The Dow''s most active stock was Apple Inc. , which ran up 2.0%, while the worst performer was Amgen Inc.''s stock, which gained 0.7%. The Dow''s rally took the index back above the June closing low, a little more than a week after closing below it on Sept. 23 to take the current bear market to a new phase. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Dr. Puhlmann has over 20 years of oncology drug development experience and has spearheaded the global development and approval of multiple cancer drugs CORALVILLE, IA / ACCESSWIRE / October 4, 2022 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced the appointment of Markus Puhlmann, MD, MBA as Chief Medical Officer (CMO). "Markus joins Viewpoint with an impressive track record of building and leading successful oncology programs," said Thijs Spoor, CEO of Viewpoint Molecular Targeting. "His broad, global experience across many tumor types at all stages of clinical development make him the ideal candidate to join Viewpoint as CMO. I am thrilled to have Markus on our management team and look forward to working together." Dr Puhlmann has 20 years of experience in oncology drug development in solid and liquid tumor indications.

Major players in the peptide therapeutics market are Amgen, Inc. , Pfizer, Inc. , Bristol-Myers Squibb Company, Sanofi, AstraZeneca plc, Novartis AG, Teva Pharmaceutical Industries Ltd. , Bachem Holding AG, Takeda Pharmaceutical Company Limited, Galena Biopharmaceuticals, Arch Biopartners, Arch Biopartners Inc. Major players in the peptide therapeutics market are Amgen, Inc. , Pfizer, Inc. , Bristol-Myers Squibb Company, Sanofi, AstraZeneca plc, Novartis AG, Teva Pharmaceutical Industries Ltd. , Bachem Holding AG, Takeda Pharmaceutical Company Limited, Galena Biopharmaceuticals, Arch Biopartners, Arch Biopartners Inc.

Monday''s top analyst upgrades and downgrades included Amgen, CarMax, Centene, CrowdStrike, Intuit, Micron Technology, Microsoft, Nike, NOV, Roblox, Unity Software and Wells Fargo.

Amgen''s stock (AMGN) surged in the intraday levels, amid positive signals from the RSI after …

Lung cancer drugs from Amgen and Mirati can barely be separated on efficacy. Read why AMGN has first mover advantage but MRTX may have a slight edge.

Sorrento Therapeutics (SRNE) said that patients with rheumatoid arthritis who received Amgen''s (AMGN) Enbrel (etanercept) though the company''s Sofusa Lymphatic Drug Delivery…

Amgen''s profitability has been struggling since 2018. Huge buybacks and rising dividends are weakening the financial structure too much. Read more here.

Wednesday''s top analyst upgrades and downgrades included Amgen, AppLovin, Blue Owl Capital, Dell Technologies, Dow, Marvell Technology, PayPal, RingCentral, Shopify, SoFi Technologies, Twilio, Western Digital, WiPro and Wolfspeed.

Amgen (AMGN) shares reached the lowest level since March as Wall Street reacted to the company''s latest update on KRAS inhibitor Lumakras, while Bristol Myers (BMY) introduced a new…

Amgen Inc (NASDAQ: AMGN ) announced the presentation of long-term data from the CodeBreaK 100 Phase 1/2 trial of Lumakras (sotorasib) in KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). In the long-term, two-year analysis of 174 heavily pretreated patients, Lumakras demonstrated a centrally confirmed objective response rate (ORR) of 40.7%, … Full story available on Benzinga.com

piframe title="Amgen und Biogen Schlagen diese beiden Biotech-Urgesteine bald zurck?" width="475" height="267" src="https://www.youtube.com/embed/abu7F90gWEM?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; …/p

Equities in North America displayed their nerves Wednesday, with central banks openly discussing rate hikes for the very near future. The TSX Composite Index lost 142.23 points to conclude midweek Wednesday at 21,788.60. The Canadian dollar fell 0.31 cents to 79.79 cents U.S. Tech proved the biggest anchor on the index, with Lightspeed POS down $3.07, or 7.7%, to $36.63, and Shopify sagged $54.61, or 6.3%, to $823.86. Real-estate was also a worry, as InterRent REIT dropped 57 cents, or 3.8%, to $14.57, while Allied Properties REIT faltered $1.45, or 3.1%, to $44.69. In energy, Whitecap Resources moved earthward 48 cents, or 4.6%, to $9.88, while Vermilion Energy slid $1.58, or 5.9%, to $25.27. Utilities was strongest fop the gainers, as Transalta copped 50 cents, or 3.8%, to $13.57, while Boralex advanced $1.96 or 3.4%, to $41.56. Communications became green in the afternoon, with Quebecor tacking on 76 cents, or 2.5%, to $31.27, while Cogeco Communications moved forward $1.51, or 1.4%, to $105.86.

Stocks fell for a second day on Wednesday and rates soared to new heights as the Federal Reserve gave more guidance on how fast it will tighten monetary policy to fight inflation, raising concerns it may slow the economy. The Dow Jones Industrials plummeted 144.67 to end the session at 34,496.51. The S&P 500 dumped 43.97 points to 4,481.15 The NASDAQ Composite wilted 315.35 points, or 2.2%, to 13,888.82. The Fed’s release of its meeting minutes indicated on Wednesday afternoon that officials “generally agreed” it should shrink its balance sheet by $95 billion per month. The minutes also showed the central bank was considering larger rate hikes than its usual 25-basis-point, or quarter-point, increments. As the Fed hikes rates, investors have begun searching for stocks with stable profits and shying away from those offering future growth. That includes the utilities, health care and consumer staples sectors — which continued to climb Wednesday, with Amgen and Johnson & Johnson rising about 2% each.

Amgen Inc. (NASDAQ:AMGN) traded at $250.15 at last check on Wednesday, April 06, made an upward move of 2.29% on its previous day’s price. Looking at the stock we see that its previous close was $244.56 and the beta (5Y monthly) reads 0.64 with the day’s price range being $243.74 – $248.75. The company has … Is Amgen Inc. (NASDAQ: AMGN) Still A Good Investment? Read More »